Pan-cancer proteogenomics reveals potential drug targets

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients. xxx:more

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

May 31, 2024

Vol.50 No.22

In Brief

Shanda Blackmon named director of Baylor’s Lung Institute

Shanda H. Blackmon was named director of the Lung Institute at Baylor Medicine.

April 26, 2024

Vol.50 No.17

Clinical Roundup

Decoding the genes behind dolastatin 10 paves the way for new cancer therapeutics

University of Florida College of Pharmacy researchers have pinpointed the genetic blueprints behind dolastatin 10, a marine natural product that has led to six FDA-approved cancer drugs since 2011.

February 16, 2024

Vol.50 No.07

Clinical Roundup

Novel assay improves detection of potential therapeutic tumor targets in human biopsies

Researchers at Baylor College of Medicine and collaborating institutions developed a kinase inhibitor pulldown assay that can optimally enrich and quantify the small amounts of kinases present in biopsy samples in combination with mass-spectrometry techniques.

January 19, 2024

Vol.50 No.03

In Brief

Baylor’s culinary event raises $6.2 million for cancer research

Chef Chris Haatuft serves guests at the BCM Culinary Stars Shine for Cancer Research.Baylor College of Medicine’s Culinary Stars Shine for Cancer Research event raised $6.2 million to support cancer research at Baylor’s Dan L Duncan Comprehensive Cancer Center.

January 05, 2024

Vol.50 No.01

Pan-cancer proteogenomics reveals potential drug targets

YOU MAY BE INTERESTED IN

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Shanda Blackmon named director of Baylor’s Lung Institute

Decoding the genes behind dolastatin 10 paves the way for new cancer therapeutics

Novel assay improves detection of potential therapeutic tumor targets in human biopsies

Baylor’s culinary event raises $6.2 million for cancer research

Renew today!

Subscriber content

Login